Rheumatoid Arthritis News

Biomarkers in blood and plasma can be used to predict rheumatoid arthritis-associated interstitial lung disease more accurately than clinical risk factors alone, suggesting potential new opportunities in screening and treatment, data show.

In rheumatology, there is always more to learn — even when it comes to the most well-trod topics and commonly researched conditions.

A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement system in human tissue, a discovery that could reshape the treatment of many rheumatic and autoimmune diseases.

The risk for all-cause and cardiovascular disease mortality was heightened when adults had arthritis plus comorbid COPD, according to data published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.

Increasing wildfire incidence, along with greater overall air pollution, may be contributing to risks for rheumatoid arthritis and RA-associated interstitial lung disease, according to findings published in Arthritis & Rheumatology.

Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases.

A risk prediction score that uses machine learning and a patient’s genetic information may identify autoimmune conditions up to 1,000% more accurately than current models, according to findings published in Nature Communications.

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or prostate cancer, according to data published in The Lancet Rheumatology.